Alumis’ (ALMS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Alumis (NASDAQ:ALMS) in a report released on Friday,Benzinga reports. They currently have a $26.00 price target on the stock.

ALMS has been the subject of several other research reports. Robert W. Baird began coverage on shares of Alumis in a report on Thursday, October 31st. They issued an “outperform” rating and a $25.00 target price for the company. Baird R W raised shares of Alumis to a “strong-buy” rating in a research note on Thursday, October 31st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Alumis in a research note on Thursday, November 14th. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $26.83.

Alumis Price Performance

Shares of Alumis stock opened at $8.82 on Friday. The business has a 50 day moving average of $10.21. Alumis has a one year low of $7.66 and a one year high of $13.53.

Institutional Trading of Alumis

Large investors have recently modified their holdings of the company. BNP Paribas Financial Markets bought a new stake in Alumis during the 3rd quarter valued at $27,000. MetLife Investment Management LLC purchased a new stake in Alumis in the third quarter worth about $89,000. Barclays PLC purchased a new stake in Alumis in the third quarter worth about $197,000. Maven Securities LTD purchased a new position in Alumis during the 2nd quarter valued at about $332,000. Finally, Towerview LLC raised its holdings in shares of Alumis by 22.6% in the 3rd quarter. Towerview LLC now owns 380,000 shares of the company’s stock valued at $4,058,000 after purchasing an additional 70,000 shares in the last quarter.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.